New drug SAT-3247 tested for long-term muscle protection in duchenne MD

NCT ID NCT06867107

ENROLLING_BY_INVITATION Disease control Sponsor: Satellos Bioscience, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the long-term safety and effects of a drug called SAT-3247 in 10 people with Duchenne muscular dystrophy who were in a previous trial. Participants take the drug by mouth five days a week for about 11 months. Researchers will check for side effects and measure changes in muscle fat and strength.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAT-3247 (a drug taken by mouth that may help muscle repair)
What this could lead to: If it works, this could point toward a treatment that slows muscle damage in Duchenne muscular dystrophy.
What could go wrong: This is a very small, early-phase study with only 10 participants, so results may not apply to everyone. The drug's long-term safety and effectiveness are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENNE MUSCULAR DYSTROPHY (DMD)

Contacts and locations

Locations

St. Vincent Hospital

Melbourne, Victoria, Australia
The Royal Children's Hospital

Melbourne, Victoria, 3052, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.